AbbVie

News

Schizophrenia highlighted in a list of definitions of disorders

Advantage BMS as AbbVie drug fails schizophrenia trials

Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.

News

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing.

News

AbbVie gets continuous Parkinson's drug over the line in US

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.

Oncology

Nicole Raleigh interview with Daejin Abidoye at ESMO 2024

ESMO 2024 - Daejin Abidoye

At ESMO 2024, AbbVie presented new data across their solid tumour pipeline, displaying the company’s potential as an emerging leader in solid tumours.

News

Blue Shield of California bypasses PBMs to slash Humira pric...

Blue Shield of California is pioneering a strategy that bypasses traditional pharmacy benefit managers to slash the price of Humira by up to 90%

News

AbbVie faulted for misleading ad featuring Serena Williams

Pharma giant AbbVie has been taken to task by the FDA for running an ad for one of its migraine drugs, featuring tennis star Serena Williams, which the agency says overstates its efficacy.<

Advantage BMS as AbbVie drug fails schizophrenia trials

AbbVie gets bigger in Alzheimer's R&D with Aliada takeover

AbbVie gets continuous Parkinson's drug over the line in US

ESMO 2024 - Daejin Abidoye

Blue Shield of California bypasses PBMs to slash Humira pric...

AbbVie faulted for misleading ad featuring Serena Williams

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks